Member Info for ROCKZ

I did ask the Accustem question after she replied to myself previously that news was due before Christmas.
She couldn’t discuss Accustem..
Either news is due any moment and she can’t comment as it’s price sensitive or there’s been a delay until after Christmas (2021!).

I’ve spoken to Hana today who advised me to speak to my broker as everything is in order Tiziana’s end.
She was also willing to speak to my broker if they required.
Anyway, spoke to my broker, Lloyds/Halifax who confirmed that the share distribution process was still ongoing at the brokers end.
She was unable to comment on Accustem but agreed that news for either company would provide a much needed boost to sentiment. She has fed these thoughts back to the BOD previously.

I got through on the 14th December and spoke to Hana.
Accustem news before Christmas I was told. Let’s see..

Appletree, Hana Malik is the company IR contact although the company are sadly lacking in this department. Best to try the phone, that’s your best bet although it can be a long shot in my experience 02074952379.
I’ve sent Emails in the past but they don’t respond so I wouldn’t waste your time.
(I sound negative from that post but still believe we will see something positive soonish). ATB

We should have all invested in SNG!
Those barstewards have had an armchair ride over there apart from that drop upon the vaccine news dropping last year.
This has been brutal over here for shareholders. Relentless stuff, 10 per cent down earlier.
It’s like swimming with hungry sharks!

Dunk, I don’t expect many inexperienced investors will be reading this LSE message board (previously a TILS) board thinking they need to desperately go and invest in TLSA on the Nasdaq tomorrow!
Not the actions of an inexperienced investor and I’m sure investors here are wise enough without being told to look out for rampers or derampers.
If an investor did invest tomorrow morning and news does drop shortly (as some of us have been told) I’m sure they will do very well so I wouldn’t get too stressed out for them.

Proof of concept is around the corner in 2022 for Foralumab and it’s being progressed by Dr Howard Weiner of Harvard university.
There’s no ramping there, that’s the facts.
We might see a JV or even a MA before Phase 3 starts as Tiziana have some very unique platform tech on their hands.

I don’t want to see TLSA sold at the moment, too cheap.
That was the reason for moving to the Nasdaq, to achieve price parity with the likes of PRVB.
I can’t see them letting Foralumab go at the moment when it is on the verge of great things.
Milciclib, yes, maybe. If the Japanese or others pay the right price. GC has mentioned the potential demerger of Milciclib in the past.

Nice holding Rocha, I’m sure it will come good.
Good username also, named after one of my ex favourite Portsmouth players, Ricardo Rocha.
There’s also the Japanese agreement with Takawana and the arrangement with Precision Bio. A pair of reputable companies who I’m sure would not want to get involved in any shenanigans which could reflect badly on their own companies and SP’s.

Axe, I think you’re wide of the mark there.
You need to distinguish between a share price fall and a downfall as you put it.
I would class a company like Quindell as having a downfall after a smoke and mirrors operation.
At this point Tiziana is suffering after the poor demerger of one company (Accustem) and the poor re-structuring of another (TILS/TLSA).
Throw in some missed deadlines and it’s been a poor year but I don’t believe there’s anything more sinister than that.

Well 2022 can’t be any worse than this year for the company!
It just feels very bearish at the moment but GC was still buying fairly recently.
The guys involved in both the running and the science of the company seem pretty decent to me and I’m not sure they are ruthless enough to give shareholders the biggest shafting of all time, as has been suggested by some.

0.36p equivalent on the Nasdaq this evening.
SP has taken a battering.
Come on BOD, help us out here..

Another quiet week. Maybe they’re locked in talks with the Japanese for the sale of Milciclib!

Ice, join the club, taken a hit here also.
I do believe though that shareholders who have invested all the way upto £2.00 will get their chance to exit at some point in 2022 with some profit.
Volume is rubbish on the Nasdaq. I suspect that even those investors who know the company well are struggling to justify exposing themselves much more. I have had a minor dabble buying TLSA but this slide has been relentless and painful for many.

You would think the BOD would be desperate to deliver something positive this year.
They may have been working away like mad in the background but I’m afraid just one person being dosed in the calendar year looks like abysmal progress.

4D is looking good value. I’m hoping this makes a move first then I will take a small position myself over there. Also fancy ARDS on the Nasdaq for a small amount.

Morning Bluebelly, last men standing haha! Still expecting some sort of news before the years out.
We could move quickly when it does drop. Fingers crossed.

Hana said to me recently that Accustem news would be out before Christmas.
I have purchased again today with that in mind.
And yes, I’m aware of broken promises and previous missed deadlines.
Taken my chances…

Some decent genuine buys in the last half an hour rather than the autobot churning over 100 at a time.
Stock price has reacted accordingly, 12 per cent up for the day.
Still small volume at the moment, this will get very interesting in the coming days/weeks.

Pretty swift move in the last hour on not huge volume.
Imagine when news drops, stock price is really going to motor.